Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4%Ophthalmic Formulation

Ophthalmology and Therapy

Volumn 3, Issue 1-2, 2014, Pages 63-72

  Schopf, Lisa ^a   Enlow, Elizabeth ^a   Popov, Alexey ^a   Bourassa, James ^a   Chen, Hongming ^a  

^a Kala Pharmaceuticals   (United States)

Author keywords

Loteprednol etabonate; Mucous; Mucus; Ocular; Ophthalmic; Ophthalmology; Pharmacokinetic; Rabbit; Steroid; Topical

Indexed keywords

DRUG CARRIER; LOTEPREDNOL ETABONATE; MUCUS PENETRATING PARTICLE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AQUEOUS HUMOR; AREA UNDER THE CURVE; ARTICLE; BLOOD ANALYSIS; CILIARY BODY; CONJUNCTIVA; CONTROLLED STUDY; CORNEA; DRUG FORMULATION; DRUG HALF LIFE; EYE EXAMINATION; IRIS; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RABBIT; RETINA; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84914705745     PISSN: 21938245     EISSN: 21936528     Source Type: Journal    
DOI: 10.1007/s40123-014-0021-z     Document Type: Article

References (23)

1. Bodor N, Loftsson T, Wu WM. Metabolism, distribution, and transdermal permeation of a soft corticosteroid, loteprednol etabonate. Pharm Res. 1992;9(10):1275–8.
2. Bodor N, Buchwald P. Ophthalmic drug design based on the metabolic activity of the eye: soft drugs and chemical delivery systems. AAPS J. 2005;7(4):E820–33.
3. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for the treatment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol. 2004;138(3):444–57.
4. Dell SJ, Schulman DG, Lowry GM, Howes J. A controlled evaluation of the efficacy and safety of loteprednol etabonate in the prophylactic treatment of seasonal allergic conjunctivitis. Loteprednol allergic conjunctivitis study group. Am J Ophthalmol. 1997;123(6):791–7.
5. Loteprednol Etabonate US Uveitis Study Group. Controlled evaluation of loteprednol etabonate and prednisolone acetate in the treatment of acute anterior uveitis. Am J Ophthalmol. 1999;127(5):537–44.
6. Asbell P, Howes J. A double-masked, placebo-controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. CLAO J. 1997;23(1):31–6.
7. Friedlander MH, Howes J. A double-masked, placebo controlled evaluation of the efficacy and safety of loteprednol etabonate in the treatment of giant papillary conjunctivitis. Loteprednol etabonate giant papillary conjunctivitis study group I. Am J Ophthalmol. 1997;123(4):455–64.
8. Stewart R, Horwitz B, Howes J, Novack GD, Hart K. Double-masked, placebo-controlled evaluation of loteprednol etabonate 0.5% for postoperative inflammation. Loteprednol Etabonate Post-operative Inflammation Study Group I. J Cataract Refract Surg. 1998;24(11):1480–9.
9. Loteprednol Etabonate Postoperative Inflammation Study Group 2. A double-masked, placebo-controlled evaluation of 0.5% loteprednol etabonate in the treatment of postoperative inflammation. Ophthalmology. 1998;105(9):1780–6.
10. Comstock TL, Paterno MR, Singh A, Erb T, Davis E. Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery. Clin Ophthalmol. 2011;5:177–86.
11. Bartlett JD, Horwitz B, Laibovitz R, Howes JF. Intraocular pressure response to loteprednol etabonate in known steroid responders. J Ocul Pharmacol. 1993;9(2):157–65.
12. Novack GD, Howes J, Crockett RS, Sherwood MB. Change in intraocular pressure during long-term use of loteprednol etabonate. J Glaucoma. 1998;7(4):266–9.
13. Comstock TL, DeCory HH. Advances in corticosteroid therapy for ocular inflammation: loteprednol etabonate. Int J Inflam. 2012;2012:789623.
14. King-Smith PE, Fink BA, Fogt N, Nichols KK, Hill RM, Wilson GS. The thickness of the human precorneal tear film: evidence from reflection spectra. Invest Ophthalmol Vis Sci. 2000;41(11):3348–59.
15. Prydal JI, Artal P, Woon H, Campbell FW. Study of human precorneal tear film thickness and structure using laser interferometry. Invest Ophthalmol Vis Sci. 1992;33(6):2006–11.
16. Prydal JI, Campbell FW. Study of precorneal tear film thickness and structure by interferometry and confocal microscopy. Invest Ophthalmol Vis Sci. 1992;33(6):1996–2005.
17. Mantelli F, Argueso P. Functions of ocular surface mucins in health and disease. Curr Opin Allergy Clin Immunol. 2008;8:477–83.
18. Gaudana R, Anathula HK, Parenky A, Mitra AK. Ocular drug delivery. AAPS J. 2010;12(3):348–60.
19. Lai SK, O’Hanlon DE, Harrold S, Man ST, Wang YY, Cone R, Hanes J. Rapid transport of large polymeric nanoparticles in fresh undiluted human mucus. PNAS. 2007;104:1482–7.
20. Druzgala P, Wu WM, Bodor N. Ocular absorption and distribution of loteprednol etabonate, a soft steroid, in rabbit eyes. Curr Eye Res. 1991;10(10):933–7.
21. Popov A, Enlow EM, Bourassa J, Gardner CR, Chen H, Ensign LM et al., inventors; Kala Pharmaceuticals, Inc., Johns Hopkins University, assignees. Pharmaceutical nanoparticles showing improved mucosal transport. World patent application WO/2013/166385. 2013 Nov 7.
22. Draize JH, Woodard G, Calvery HO. Methods for the study of irritation and toxicity of substances applied topically to the skin and mucous membranes. J Pharmacol Exp Ther. 1944;82:377–90.
23. Ludwig A. The use of mucoadhesive polymers in ocular drug delivery. Adv Drug Deliver Rev. 2005;57:1595–639.